Scientists hunt for clues to breast cancer treatment resistance
NCT ID NCT06518382
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examines tumor samples from 10 people with HER2-positive breast cancer who still had cancer after standard chemotherapy and trastuzumab. Researchers compare tissue taken before and after treatment to identify markers of resistance. No new treatments are given; the goal is to better understand why some cancers don't respond.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
IRCCS San Raffaele Hospital
RECRUITINGMilan, Lombardy, 20132, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••